CRP and familial dilated cardiomyopathy: In DCM patients with high DNI and CRP levels—particularly when EF is borderline or mildly reduced—closer clinical follow-up, more aggressive optimization of medical therapy, and earlier consideration of advanced imaging or device therapies may provide meaningful benefits in personalized risk management.